biotech / news / / Benzinga
The STEP UP trial evaluated semaglutide 7.2 mg, 2.4 mg, and placebo over 72 weeks.
Participants taking 7.2 mg Wegovy lost an average of 21% of their body weight over 72 weeks.
KEY POINTS
- New STEP UP analysis shows 27% of 7.2 mg patients were early responders, losing ≥15% in 24 weeks.
- MRI sub-analysis found 84% of semaglutide-induced weight loss was from reduced fat mass.
- Muscle function was preserved as assessed by a sit-to-stand test despite muscle mass reduction.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →